Nu Chai, MD
Interventional Pain Medicine · San Francisco, CANPI 1073830477
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,825 of the $25,946 with a category attached, or 68.7%. Averitas Pharma Inc. accounts for 95.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $20,745 and has fallen 96.9% since, to $642 in 2025.
Across 65 payments — averaging $399.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Averitas Pharma Inc.$25K
- Biotronik NRO, Inc.$489
- Bioventus LLC$170
- AbbVie$129
- Nevro Corp.$110
- Tersera Therapeutics LLC$64
- plus $190 from 4 others
What the payments were for
- Speaking & faculty fees$17,82569%
- Travel & lodging$6,43025%
- Food & beverage$1,6907%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Averitas Pharma Inc. | 44 | $24,793 |
| Biotronik NRO, Inc. | 6 | $489 |
| Bioventus LLC | 3 | $170 |
| AbbVie | 4 | $129 |
| Nevro Corp. | 1 | $110 |
| Tersera Therapeutics LLC | 2 | $64 |
| MML US, Inc. | 1 | $57 |
| Stryker | 2 | $52 |
| Boston Scientific | 1 | $47 |
| Vertex | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$24,365
- Prospera$296
- Omnia$110
- Stimrouter Implantable Kit$103
How this compares
$25,946 in reported general payments places this provider in the 85th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aimovig AutoinjectorErenumab-Aooe | 11 | $7,618 |
| Pregabalin | 38 | $1,474 |
| Duloxetine Hcl | 43 | $800 |
| Cyclobenzaprine Hcl | 13 | $164 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in San Francisco
- Lawrence PoreeSan Francisco$111K
- Conor O NeillSan Francisco$16K
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.